Journal of Gastroenterology

, Volume 30, Issue 4, pp 461–464 | Cite as

A proton pump inhibitor, E3810, has antibacterial activity through binding toHelicobacter pylori

  • Masamichi Hirai
  • Takeshi Azuma
  • Shigeji Ito
  • Takuji Kato
  • Yoshihiro Kohli
Alimentary Tract


Helicobacter pylori infection is causally related to atrophic gastritis, and it may also be associated with peptic ulcer and gastric carcinoma. Eradication ofH. pylori is recommended in patients with such diseases, especially in those with peptic ulcer. A new potent proton pump inhibitor, E3810, had an antibacterial effect onH. pylori, as has been reported for omeprazole and lansoprazole, two other proton pump inhibitors. The minimum inhibitory concentration of E3810 was 1.57–3.13 μg/ml, lower than that of omeprazole or lansoprazole. To clarify the mechanism of the antibacterial effect of E3810, we analyzed the characteristics of E3810 binding toH. pylori. Scatchard plot analysis of this binding showed a curvilinear profile, indicating the presence of several molecules with different affinities to E3810 onH. pylori. The binding capacity of E3810 toH. pylori was calculated to be about 2×106 sites/cell. These results suggested that E3810 has an antibacterial effect againstH. pylori and that the effect may be mediated through direct binding toH. pylori.

Key words

Helicobacter pylori proton pump inhibitor Scatchard plot analysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;I:1273–1275.Google Scholar
  2. 2.
    Blaser MJ. GastricCampylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology 1987;93:371–383.PubMedGoogle Scholar
  3. 3.
    Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication ofCampylobacter pylori. Lancet 1988;II:1437–1442.Google Scholar
  4. 4.
    Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication ofHelicobacter pylori. Lancet 1990;335:1233–1235.CrossRefPubMedGoogle Scholar
  5. 5.
    Hentschel E, Brandstätter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication ofHelicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308–312.CrossRefPubMedGoogle Scholar
  6. 6.
    Helicobacter pylori peptic ulcer disease. National Institutes of Health Consensus Development Conference; 1994 Feb 7–9; Bethesda. Bethesda: National Institutes of Health, 1994.Google Scholar
  7. 7.
    Borody T, Cole P, Noonan S, et al. Long-termCampylobacter recurrence post-eradication (abstract). Gastroenterology 1988; 94:A43.Google Scholar
  8. 8.
    Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity againstHelicobacter pylon. Antimicrob Agents Chemother 1991;35:490–496.PubMedGoogle Scholar
  9. 9.
    Adamek RJ, Wegener M, Labenz J, et al. Medium-term results of oral and intravenous omeprazole/amoxicillinHelicobacter pylori eradication therapy. Am J Gastroenterol 1994;89:39–42.PubMedGoogle Scholar
  10. 10.
    Fujisaki H, Shibata H, Oketani K, et al. Effects of the proton pump inhibitor, E3810, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Drug Invest 1991;3:328–332.Google Scholar
  11. 11.
    Scatchard G. Some physical chemical aspects of “plasma extenders”. Ann NY Acad Sci 1952;55:455–464.PubMedGoogle Scholar
  12. 12.
    Labenz J, Rühl GH, Bertrams J, et al. Medium- or high-dose omeprazole plus amoxicillin eradicatesHelicobacter pylori in gastric ulcer disease. Am J Gastroenterol 1994;89:726–730.PubMedGoogle Scholar
  13. 13.
    Van Zanten SJO, Goldie J, Hollingsworth J, et al. Secretion of intravenously administered antibiotics in gastric juice: Implications for management ofHelicobacter pylori. J Clin Pathol 1992;45:225–227.PubMedGoogle Scholar
  14. 14.
    Hunt RH. pH and Hp-Gastric acid secretion andHelicobacter pylori: Implication for ulcer healing and eradication of the organism (editorial). Am J Gastroenterol 1993;88:481–483.PubMedGoogle Scholar
  15. 15.
    Mauch I, Bode G, Malfertheiner P. Identification and characterization of an ATPase system ofHelicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993;88:1801–1802.PubMedGoogle Scholar
  16. 16.
    Nagata K, Satoh H, Iwahi T, et al. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity ofHelicobacter pylori: Unique action selective forH. pylori cells. Antimicrob Agents Chemother 1993;37:769–774.PubMedGoogle Scholar
  17. 17.
    Segal ED, Shon J, Tompkins LS. Characterization ofHelicobacter pylori urease mutants. Infect Immun 1992;60:1883–1889.PubMedGoogle Scholar
  18. 18.
    McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival ofHelicobacter pylori by a urease-independent mechanism. Gastroenterology 1994;107: 738–743.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Masamichi Hirai
    • 1
  • Takeshi Azuma
    • 1
  • Shigeji Ito
    • 1
  • Takuji Kato
    • 1
  • Yoshihiro Kohli
    • 1
  1. 1.Second Department of Internal MedicineFukui Medical SchoolFukuiJapan

Personalised recommendations